The transition from first-line to second-line therapy in multiple sclerosis.
about
Current status of biomarker research in neurologyUltrahigh field MRI in clinical neuroimmunology: a potential contribution to improved diagnostics and personalised disease managementRationale, design, and methods of a non-interventional study to establish safety, effectiveness, quality of life, cognition, health-related and work capacity data on Alemtuzumab in multiple sclerosis patients in Germany (TREAT-MS).Analysis of Lymphocytic DNA Damage in Early Multiple Sclerosis by Automated Gamma-H2AX and 53BP1 Foci Detection: A Case Control Study.Comparison of Sleep Problems in Individuals with Spinal Cord Injury and Multiple SclerosisMultiple sclerosis and primary vascular dysregulation (Flammer syndrome)Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.Guideline for multiple sclerosis treatment in Brazil: Consensus from the Neuroimmunology Scientific Department of the Brazilian Academy of Neurology.Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study.The Italian Pharmacovigilance Program: An Observational Study of Adverse Effects of Natalizumab in Multiple Sclerosis Therapy.Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMSVitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases.Association of Retinal Ganglion Cell Layer Thickness With Future Disease Activity in Patients With Clinically Isolated Syndrome.
P2860
Q26744505-D1490640-FBFC-4FE2-9822-A2829FC5CE49Q26796643-1FFD3867-C9E3-4CEF-8E30-B89722DEFFE3Q31115496-F8EB4E93-724D-4C71-9B79-40B9F6153084Q35907244-F63E77B6-7573-450C-A9E5-EED7183AED37Q36897062-78E2E716-9BD1-4EDF-98A3-0BCDA6B3A6F2Q37006428-C69545F5-DE23-4340-BF71-89606921A39AQ37615119-8BE0EB6F-4E5B-40F8-B63F-38AAC54CACD9Q39093778-01B067CE-CA63-4941-8E46-9097A487AE0EQ39675286-A23BD248-3C03-483C-AB6B-422CE038CB54Q41381386-C356E130-3D83-405A-BAF5-5482BCF090B2Q41571171-B2DC8DFD-0607-4454-BFF8-EF43606ED755Q47163794-086EF602-A057-4698-8B69-0E83BE0125FBQ52803927-F98CFC76-D7ED-4736-A103-4885BB46C35F
P2860
The transition from first-line to second-line therapy in multiple sclerosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The transition from first-line to second-line therapy in multiple sclerosis.
@en
type
label
The transition from first-line to second-line therapy in multiple sclerosis.
@en
prefLabel
The transition from first-line to second-line therapy in multiple sclerosis.
@en
P2860
P1476
The transition from first-line to second-line therapy in multiple sclerosis.
@en
P2093
P2860
P2888
P356
10.1007/S11940-015-0354-5
P577
2015-06-01T00:00:00Z
P5875
P6179
1000190249